Search

Your search keyword '"Cobimetinib"' showing total 33 results
Start Over Descriptor "Cobimetinib" Publisher business wire, inc.
33 results on '"Cobimetinib"'

1. Exelixis In-Licenses Aurigene's Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors

Subjects
United States. Food and Drug Administration, Exelixis Inc. -- Product development, Cabozantinib, Cobimetinib, Chemotherapy, Biotechnology industries -- Product development, Tumors, Business, Business, international
Abstract

- Phase 1 clinical trial expected to begin in Q1 2021 - - Under the terms of the companies' agreement, Exelixis will make an option exercise payment of $12 million [...]

Published
2020

2. Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

Subjects
United States. Food and Drug Administration, Exelixis Inc. -- Product development, Cabozantinib, Cobimetinib, Biotechnology industries -- Product development, Biopharmaceuticals -- Product development, Antibodies, Business, Business, international
Abstract

- Phase 1 clinical trial planned for early 2021, pending the FDA's acceptance of Exelixis' planned IND filing - - Under the terms of the companies' agreement, Exelixis has made [...]

Published
2020

3. Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December

Subjects
Exelixis Inc., Cabozantinib, Cobimetinib, Biotechnology industries, Business, Business, international
Abstract

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at [...]

Published
2020

4. Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor

Subjects
Exelixis Inc., Cabozantinib, Atezolizumab, Cobimetinib, Tyrosine, Biotechnology industries, Vascular endothelial growth factor, Phenols (Class of compounds), Business, Business, international
Abstract

- In preclinical studies, XL092 demonstrated robust target and tumor growth inhibition - - Clinical pharmacokinetic (PK) data suggest a significantly shorter half-life than cabozantinib - - Phase 1 evaluation [...]

Published
2020

5. Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

Subjects
Exelixis Inc. -- Licensing agreements -- Product development, Cabozantinib, Cobimetinib, Tumors -- Drug therapy, Biological products -- Product development -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

- ICON-2 is pharmacologically more potent in vivo and in vitro, with better nonclinical tolerability, compared with a monomethyl auristatin E (MMAE) anti-TF antibody-drug conjugate (ADC) - - Data presented [...]

Published
2020

6. Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

Subjects
Morgan Stanley, Exelixis Inc., Cabozantinib, Securities industry, Cobimetinib, Biotechnology industries, Securities industry, Business, Business, international
Abstract

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at [...]

Published
2020

7. Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma

Subjects
Exelixis Inc., Roche Holding AG, Clinical trials, Atezolizumab, Cobimetinib, Biotechnology industries, Renal cell carcinoma, Cancer metastasis, Antineoplastic agents, Business, Business, international, Cabometyx (Medication)
Abstract

- CONTACT-03 is the third of three phase 3 pivotal trials that are part of a clinical collaboration with Roche - ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ: EXEL) today announced [...]

Published
2020

8. Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer

Subjects
Takeda Pharmaceutical Company Ltd., Exelixis Inc., Roche Holding AG, Clinical trials, Atezolizumab, Cobimetinib, Biotechnology industries, Prostate cancer -- Care and treatment, Pharmaceutical industry, Cancer metastasis -- Care and treatment, Antineoplastic agents, Business, Business, international, Cabometyx (Medication)
Abstract

- Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial - - CONTACT-02 is the second of three phase 3 pivotal trials that are part of a [...]

Published
2020

9. Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer

Subjects
Exelixis Inc., Roche Holding AG, Cabozantinib, Atezolizumab, Cobimetinib, Chemotherapy, Biotechnology industries, Small cell lung cancer, Sorafenib, Prostate cancer, Non-small cell lung cancer, Cancer metastasis, Cancer treatment, Lung cancer, Business, Business, international, Cabometyx (Medication)
Abstract

- Initiation follows positive results from cohort 7 of phase 1b COSMIC-021 trial - - CONTACT-01 is the first of three phase 3 pivotal trials that are part of a [...]

Published
2020

10. Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June

Subjects
The Goldman Sachs Group Inc., Exelixis Inc., Financial markets, Cabozantinib, Investment banks, Cobimetinib, Biotechnology industries, Business, Business, international
Abstract

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis' management team will participate in fireside chats at the [...]

Published
2020

11. Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May

Subjects
Exelixis Inc., Cabozantinib, Cobimetinib, Biotechnology industries, Business, Business, international
Abstract

-- Presentations to be webcast on www.exelixis.com -- ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis' management team will participate in fireside chats at the [...]

Published
2020

12. Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX[R] (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma

Subjects
Takeda Pharmaceutical Company Ltd., Exelixis Inc., Clinical trials, Cobimetinib, Biotechnology industries, Vascular endothelial growth factor, Pharmaceutical industry, Renal cell carcinoma, Cancer metastasis, Antineoplastic agents, Sorafenib, Carcinoma, Cancer, Endothelial growth factors, Phenols (Class of compounds), Health, Cabozantinib, Diseases, Tyrosine, Everolimus, Sunitinib, Business, Business, international, Cabometyx (Medication)
Abstract

ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX([R]) (cabozantinib) in Japan, received [...]

Published
2020

13. Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors

Subjects
Exelixis Inc. -- Officials and employees, Cabozantinib, Corporate directors, Cobimetinib, Biotechnology industries -- Officials and employees, Presidents (Organizations), Stockholders, Media executives, Business, Business, international
Abstract

ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that George A. Scangos, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors. Dr. [...]

Published
2020

14. Exelixis Announces Webcasts of Investor Conference Presentations in March

Subjects
Oppenheimer and Company Inc., Exelixis Inc., Cowen and Company L.L.C., Cabozantinib, Securities industry, Cobimetinib, Biotechnology industries, Securities industry, Business, Business, international
Abstract

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis' management team will provide a corporate overview at the [...]

Published
2020

15. Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer

Subjects
Exelixis Inc., Thyroid cancer, Cabozantinib, Cobimetinib, Biotechnology industries, Vascular endothelial growth factor, Radiotherapy, Sorafenib, Endothelium, Endothelial growth factors, Thyroid diseases, Business, Business, international, Cabometyx (Medication)
Abstract

- Analysis for the co-primary endpoint of objective response rate and an interim analysis of progression-free survival expected in the second half of 2020 - ALAMEDA, Calif. -- Exelixis, Inc. [...]

Published
2020

16. Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Subjects
United States. Food and Drug Administration, Exelixis Inc. -- Company sales and earnings, Cabozantinib, Atezolizumab, Cobimetinib, Biotechnology industries -- Company sales and earnings, Sorafenib, Cancer metastasis, Professional associations, Company earnings/profit, Business, Business, international, Cabometyx (Medication)
Abstract

Data from the COSMIC-021 trial will be presented on Thursday, February 13, 2020 at the American Society of Clinical Oncology's Genitourinary Cancers Symposium ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ:EXEL) today [...]

Published
2020

17. Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX[R] (cabozantinib) for Advanced Hepatocellular Carcinoma

Subjects
Takeda Pharmaceutical Company Ltd., Exelixis Inc., Cabozantinib, Cobimetinib, Hepatocellular carcinoma -- Drug therapy, Biotechnology industries, Sorafenib, Pharmaceutical industry, Carcinoma, Cancer, Clinical trials, Health, Production management, Business, Business, international, Cabometyx (Medication)
Abstract

- Submission based on two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy - ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ: EXEL) today announced that [...]

Published
2020

18. Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma

Subjects
Exelixis Inc. -- Company sales and earnings, Cobimetinib, Hepatocellular carcinoma, Nivolumab, Biotechnology industries -- Company sales and earnings, Antineoplastic agents, Ipilimumab, Sorafenib, Carcinoma, Cancer, Clinical trials, Cabozantinib, Professional associations, Company earnings/profit, Business, Business, international, Cabometyx (Medication)
Abstract

- Data from the CheckMate 040 trial presented at the 2020 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium - ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ: EXEL) today announced phase [...]

Published
2020

19. Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

Subjects
JPMorgan Chase & Co., Exelixis Inc., Cabozantinib, Cobimetinib, Biotechnology industries, Banking industry, Presidents (Organizations), Web sites (World Wide Web), Media executives, Banking industry, Business, Business, international
Abstract

-- Presentation to be webcast on www.exelixis.com -- ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will [...]

Published
2020

20. Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

Subjects
Genentech Inc. -- Company sales and earnings -- Product development, Exelixis Inc. -- Company sales and earnings -- Product development, Vemurafenib, Cabozantinib, Atezolizumab -- Product development, Cobimetinib, Gene mutation -- Genetic aspects, Biotechnology industries -- Company sales and earnings -- Product development -- Genetic aspects, Death, Biological products industry, Corporate sponsorship, Company earnings/profit, Business, Business, international, Cotellic (Medication), Zelboraf (Medication)
Abstract

ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced positive results from IMspire150, the phase 3 trial of atezolizumab (TECENTRIQ([R])), cobimetinib (COTELLIC([R])) and vemurafenib (ZELBORAF([R])) in people with previously untreated [...]

Published
2019

21. Exelixis Announces Webcasts of Investor Conference Presentations in December

Subjects
Exelixis Inc., Cabozantinib, Cobimetinib, Biotechnology industries, Business, Business, international
Abstract

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis' management team will provide an overview of the company [...]

Published
2019

22. Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019

Subjects
Exelixis Inc., Cabozantinib, Cobimetinib, Biotechnology industries, Presidents (Organizations), Web sites (World Wide Web), Media executives, Business, Business, international
Abstract

- Presentation to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will [...]

Published
2019

23. Exelixis' Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

Subjects
Exelixis Inc. -- Product development, Daiichi Sankyo Company Ltd. -- Product development, Cabozantinib, Trandolapril -- Product development, Angiotensin II -- Product development, Cobimetinib, Biotechnology industries -- Product development, Pharmaceutical industry -- Product development, Diabetic nephropathies -- Care and treatment, Kidney diseases, Professional associations, Novels, Business, Business, international
Abstract

-- Results being presented today in a late-breaking presentation (abstract TH-PO1201) at Kidney Week 2019, the annual meeting of the American Society of Nephrology in Washington, D.C. ALAMEDA, Calif. -- [...]

Published
2019

24. Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

Subjects
Exelixis Inc., Cabozantinib, Cobimetinib, Biotechnology industries, Web sites (World Wide Web), Business, Business, international
Abstract

- Presentation to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 [...]

Published
2019

25. Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019

Subjects
Morgan Stanley, Exelixis Inc., Cabozantinib, Securities industry, Cobimetinib, Biotechnology industries, Presidents (Organizations), Web sites (World Wide Web), Media executives, Securities industry, Business, Business, international
Abstract

- Presentation to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will [...]

Published
2019

26. Exelixis Announces Webcasts of Investor Conference Presentations in June 2019

Subjects
The Goldman Sachs Group Inc., Exelixis Inc., Financial markets, Cabozantinib, Investment banks, Cobimetinib, Biotechnology industries, Business, Business, international
Abstract

[?] Presentations to be webcast on www.exelixis.com [?] ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following three investor conferences in [...]

Published
2019

27. Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

Subjects
Exelixis Inc. -- Licensing agreements, Biotechnology industries -- Licensing agreements, Antibodies, Cobimetinib, Cabozantinib, Biopharmaceuticals -- Licensing agreements, Research funding, Cancer, Biological products, Company licensing agreement, Business, Business, international
Abstract

[?] ICON-2 program targets Tissue Factor (TF) with potential broad impact in oncology [?] [?] Exelixis will make upfront payment and contribute research funding for option to in-license at Investigational [...]

Published
2019

28. Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019

Subjects
Exelixis Inc., Biotechnology industries, Cobimetinib, Cabozantinib, Financial markets, Business, Business, international
Abstract

[?] Presentations to be webcast on www.exelixis.com [?] ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following two investor conferences on [...]

Published
2019

29. Exelixis' Collaborator Daiichi Sankyo Launches MINNEBRO[R] (Esaxerenone) Tablets in Japan

Subjects
Exelixis Inc., Daiichi Sankyo Company Ltd., Biotechnology industries, Pharmaceutical industry, Cobimetinib, Cabozantinib, Hypertension -- Care and treatment, Business, Business, international
Abstract

-- First commercial sale triggers $20 million milestone payment to Exelixis -- ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited ('Daiichi Sankyo') has [...]

Published
2019

30. Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma

Subjects
Exelixis Inc., Cobimetinib, Nivolumab, Biotechnology industries, Renal cell carcinoma, Antineoplastic agents, Ipilimumab, Sorafenib, Carcinoma, Cancer, Cancer metastasis, Cabozantinib, Sunitinib, Business, Business, international, Cabometyx (Medication)
Abstract

- COSMIC-313 is the third phase 3 pivotal trial to investigate cabozantinib in combination with immune checkpoint inhibitors - ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ: EXEL) today announced that it [...]

Published
2019

31. Exelixis' Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX[R] (Cabozantinib) for Advanced Renal Cell Carcinoma

Subjects
Exelixis Inc. -- Licensing agreements, Takeda Pharmaceutical Company Ltd. -- Licensing agreements, Biotechnology industries -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Nivolumab, Cobimetinib, Renal cell carcinoma, Cancer metastasis, Antineoplastic agents -- Licensing agreements, Sorafenib, Sunitinib, Everolimus, Cancer, Carcinoma, Health, Cabozantinib, Company licensing agreement, Business, Business, international, Cabometyx (Medication)
Abstract

-- Regulatory submission triggers $10 million milestone payment to Exelixis under collaboration and license agreement with Takeda -- -- Submission based on METEOR and CABOSUN trials as well as Takeda [...]

Published
2019

32. Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019

Subjects
Exelixis Inc., Biotechnology industries, Chief financial officers, Vice presidents (Organizations), Cobimetinib, Cabozantinib, Media executives, Business, Business, international
Abstract

[?] Presentation to be webcast on www.exelixis.com [?] ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ: EXEL) today announced that Christopher J. Senner, the company's Executive Vice President and Chief Financial Officer, [...]

Published
2019

33. Exelixis Announces Webcasts of Investor Conference Presentations in March

Subjects
Exelixis Inc., Cowen and Company L.L.C., Oppenheimer and Company Inc., Biotechnology industries, Securities industry, Cobimetinib, Cabozantinib, Securities industry, Business, Business, international
Abstract

[?] Presentations to be webcast on www.exelixis.com [?] ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ: EXEL) today announced that the company will be presenting at the following investor conferences in March: [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results